BioInvent International AB (STU:BIX) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is BioInvent International AB Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. BioInvent International AB's annualized positive value of Interest Expense for the quarter that ended in Dec. 2024 was €0.00 Mil. BioInvent International AB's average total debt for the quarter that ended in Dec. 2024 was €1.51 Mil. Therefore, BioInvent International AB's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 was 0.00%.

BioInvent International AB Effective Interest Rate on Debt % Historical Data

The historical data trend for BioInvent International AB's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Effective Interest Rate on Debt % Chart

BioInvent International AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

2.52

2.56

2.26

2.52

2.67

BioInvent International AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioInvent International AB's Effective Interest Rate on Debt %

For the Biotechnology subindustry, BioInvent International AB's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioInvent International AB's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Effective Interest Rate on Debt % falls into.

Save Embed

;

Save Embed

;

BioInvent International AB Effective Interest Rate on Debt % Calculation

BioInvent International AB's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2023 )	+	Total Debt (A: Dec. 2024 ))	/ count )
=	-1 * -0.048	/	( (2.078	+	1.514)	/ 2 )
=	-1 * -0.048	/	1.796
=	2.67 %

where

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.299	+	0.779
=	2.078

	Total Debt (A: Dec. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.714	+	0.8
=	1.514

BioInvent International AB's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Sep. 2024 )	+	Total Debt (Q: Dec. 2024 ))	/ count )
=	-1 * 0	/	( (1.499	+	1.514)	/ 2 )
=	-1 * 0	/	1.5065
=	0.00 %

where

	Total Debt (Q: Sep. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.732	+	0.767
=	1.499

	Total Debt (Q: Dec. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.714	+	0.8
=	1.514

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

BioInvent International AB (STU:BIX) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

BioInvent International AB Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioInvent International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (STU:BIX) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

BINV:Sweden 0H22:UK BIX0:Germany

Address

Ideongatan 1, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines